Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 6/20 | 0.61 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.61 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.61 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 6/20 | 0.35 |
| ▸ | ACACA | Q13085 | 6/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PPOX | P50336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118155 | 0.90 | PTP4A3 (0.61) | PTP4A3PTP4A2PTP4A1TDP2PTGS1 | |
| SCHEMBL22012119 | 0.82 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1TDP2PRF1 | |
| SCHEMBL22013811 | 0.82 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1TDP2PRF1 | |
| SCHEMBL22013199 | 0.79 | PTP4A3 (0.77) | PTP4A3PTP4A2PTP4A1TDP2PRF1 | |
| SCHEMBL24117878 | 0.79 | PTP4A3 (0.77) | PTP4A3PTP4A2PTP4A1PRF1 | |
| SCHEMBL22012120 | 0.79 | PTP4A3 (0.68) | PTP4A3PTP4A2PTP4A1TDP2PRF1 | |
| SCHEMBL24118160 | 0.79 | PTP4A3 (0.68) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL24117885 | 0.79 | PTP4A3 (0.68) | PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL22013197 | 0.77 | PTP4A3 (0.74) | PTP4A3PTP4A2PTP4A1PTGS2 | |
| SCHEMBL18323037 | 0.76 | PTP4A3 (1.00) | PTP4A3PTP4A2PTP4A1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221602-A2 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING LUNG INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRC, PTPRF | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 7/4885 |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRO, PTPRC | PTP4A3 1/4885PTP4A2 5/4885PTP4A1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.